DOTMATICS
30.3.2017 09:02:08 CEST | Business Wire | Press release
Dotmatics , a leading provider of scientific informatics solutions and services, today announced Reaction Workflows (RW), a major new application within the Dotmatics 5.1 suite that lets scientists quickly and easily define and execute common cheminformatics tasks, such as library enumeration, structure normalization and compound profiling, in a graphical workflow environment.
RW, part of the integrated Dotmatics 5.1 informatics suite, allows scientists to produce an easily understandable graphical record for sharing scientific best practices and knowledge retention within an organization. Scientists can develop workflows quickly and easily using an intuitive, drag-and-drop web-based interface without programming or scripting experience.
“Reaction Workflows provides the ability for any chemist within a company to easily perform an important set of cheminformatics tasks,” said Dotmatics’ Director and Chief Scientific Officer Mike Hartshorn, Ph.D. “This application complements the enhanced user experience and increased accessibility in our 5.1 platform suite by allowing scientists to perform their own ad-hoc analysis without the need for additional resources. This removes a common and time-consuming roadblock to meeting their goals.”
Intuitive User Interface
Within RW, workflows are built from nodes that provide inputs and outputs or perform actions. Using the drag-and-drop interface, the nodes are joined together to define a data process to perform. This makes designing or modifying workflows significantly faster and less prone to error than manual development without requiring specialized technical skills.
Immediate Productivity
The application includes a variety of chemically intelligent nodes including ones to perform reaction-, scaffold-, and transform-based enumeration. Nodes for performing structure normalization, property calculation, substructure annotation and filtering are also available. Other nodes read and write chemical structures and visualize the results or send them to Dotmatics Vortex for further analysis. The ability to perform the different types of enumeration in combination with property/structure annotation and filtering means it can be used for many common medicinal chemistry use cases. Nodes come populated with external content to ensure that chemists can be immediately productive. For example:
- The reaction node provides an extensive list of pre-built chemical reactions that are commonly used in synthetic and medicinal chemistry.
- The transform node provides a set of structural changes that are performed in medicinal chemistry to alter structures. Further reactions, transforms or scaffolds can be added easily.
- The reagent node is preconfigured with common sets of chemical reagents from Dotmatics Chemselector .
Chemistry teams or individuals can add and share additional reactions and other content to these stores based on proprietary corporate knowledge.
Address Wide Variety of Tasks
Reaction Workflows is a highly flexible application where multiple cheminformatics nodes can be joined together to build workflows quickly and thoroughly. Typical use cases include reaction-based enumeration, Markush-based enumeration, virtual library-enumeration, and profiling and structure normalization for registration. The application also allows scientists to create workflows for lead hopping, filtering and profiling sets of structures by properties and substructures. It even allows for the creation of workflows that address the important but mundane task of chemistry file cleanup, which allows cheminformaticians to automate the correction of errors and inconsistencies in data and structure files, prior to their use in design.
Integrates with Dotmatics Applications
RW is integrated into the Dotmatics Suite. Browser hit lists, for example, sets of reagents, can be used as input into the reagents node. A Vortex node can be inserted into a workflow so that the results of an enumeration and an interactive selection in Vortex can provide input to the next node in the workflow.
An Introducing Dotmatics Reaction Workflows webinar will be held Thursday, April 6, 2017, from 10:30-11:30 am Eastern Time. A What’s New in Dotmatics 5. 1 webinar will be held May 9, 2017, from 10:30-11:30 am Eastern Time. Dotmatics presenters Phil Mounteney, head of application science, North America and Gianpaolo Bravi, senior scientist and one of the lead developers of RW, will provide a product overview and lead a demonstration. To register for the April 6 webinar click here . To register for the May 9 webinar click here . A video of 5.1 including Reaction Workflows is available here .
About Dotmatics:
Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information visit dotmatics.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005447/en/
Contact:
Dotmatics
Marla Kertzman, +1 209-852-9027
pr@dotmatics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
